AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04505839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STP1002
Description: Oral capsule, QD
Study NCT05461833 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal transplantation
Description: Preparation of flesh feces by blending in 0.9 % saline and crude filtering. The solution is applied in proximal colon of IBS patient by colonoscopy after standard bowel preparation.
Study NCT05461833 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OTILONII BROMIDUM
Description: OTILONII BROMIDUM , oral, 40 mg TID, 1 months of treatment
Study NCT05461833 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: multi-strain probiotic
Description: multi-strain probiotic, oral, 1 capsule BID for 1 month
Study NCT04449380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-ß-1a
Description: IFNβ-1a will be administered subcutaneously at a dose of 44 mcg (equivalent to 12 million international units), three times per week at least 48 hours apart, for a total of two weeks. All patients will receive a total dose of 264 mcg (72 million international units) under physician control
Study NCT04449380 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SOC)
Description: Any pharmacological (e.g. antibiotics, etc.) and non-pharmacological (e.g. oxygen, ventilation, etc.) treatments prescribed on clinical grounds
Study NCT04640831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 Methoxy N,N Dimethyltryptamine
Description: GH001 administered via inhalation
Study NCT03270202 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAI group
Description: * physical activity defined as 100 weekly PAI during 1 year~* smartphone application and a user-friendly activity wristband (Mio PAI Slice)
Study NCT03270202 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Participants will be informed about, and encouraged to be active according to current recommendations for physical activity from the health authorities.
Study NCT03270202 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants will be informed about, and encouraged to be active according to current recommendations for physical activity from the health authorities.
Study NCT03045705 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine pain management
Description: Women that will be asked according to the routine management regarding pain management during labor, meaning frequent inquiries regarding the woman's wishes to receive analgesia by the medical team.
Study NCT03045705 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No inquiry regarding analgesia
Description: women will not be asked about analgesia during labor by the medical team, but will be able to receive the modality of choice at the time of choice.
Study NCT02086890 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Study NCT02086890 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Acupuncture
Study NCT02086890 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcorneal Electrical Stimulation
Study NCT02086890 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Electro-acupuncture
Study NCT02086890 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham laser acupuncture
Study NCT02086890 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcorneal electrical stimulation
Study NCT02138786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selinexor
Description: * 60 mg dose twice weekly, on Days 1 and 3 of weeks 1-4 of each 4-week cycle; dose may be increased to 80 mg after Cycle 1 unless clinically contraindicated (Protocol V.5.0).~* 60 mg dose twice weekly on Days 1 and 3 of weeks 1-3 of each 4-week cycle; dose may be increased to 80 mg at Cycle 3 Day 1 unless clinically contraindicated (Protocol V.4.0).~* 60 mg/m² dose, based on BSA, twice weekly, on Days 1 and 3 of weeks 1-3 of each 4-week cycle (Protocol V. 3.0).~* 60 mg/m² dose, based on BSA, twice weekly, on Days 1 and 3 of weeks 1-4 of each 4-week cycle (Protocol V. \< 3.0).
Study NCT03926195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: 200-mg tablet administered orally once daily
Study NCT03926195 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match filgotinib tablet administered orally once daily
Study NCT03926195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Locally approved treatment, accepted by medical experts as a proper treatment for rheumatic conditions, prescribed according to best clinical practice, with no known testicular toxicity.
Study NCT03926195 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Locally approved treatment, accepted by medical experts as a proper treatment for rheumatic conditions, prescribed according to best clinical practice, with no known testicular toxicity.
Study NCT01681992 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Priorix
Description: Subjects receive one dose of either minimum (Inv_MMR_Min) or medium (Inv_MMR_Med) potency lot at Day 0 and a dose of separate potency lot (Inv_MMR_Release) at Day 42, administered subcutaneously in the triceps region of the left arm.
Study NCT01681992 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: M-M-R II
Description: Subjects receive two doses of either Lot 1 or Lot 2, one at Day 0 and one at Day 42, administered subcutaneously in the triceps region of the left arm.
Study NCT01681992 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Varivax
Description: Subjects receive one dose co-administered subcutaneously with the study vaccines (Priorix and M-M-R II), in the triceps region of right arm, at Day 0.
Study NCT01681992 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varivax
Description: Subjects receive one dose co-administered subcutaneously with the study vaccines (Priorix and M-M-R II), in the triceps region of right arm, at Day 0.
Study NCT01681992 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix
Description: Subjects receive one dose co-administered intramuscularly with the study vaccines (Priorix and M-M-R II), in the anterolateral region of the right thigh, at Day 0.
Study NCT01681992 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Havrix
Description: Subjects receive one dose co-administered intramuscularly with the study vaccines (Priorix and M-M-R II), in the anterolateral region of the right thigh, at Day 0.
Study NCT01681992 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13
Description: US Subjects receive one dose co-administered intramuscularly with the study vaccines (Priorix and M-M-R II), in the anterolateral region of the left thigh, at Day 0.
Study NCT01681992 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar 13
Description: US Subjects receive one dose co-administered intramuscularly with the study vaccines (Priorix and M-M-R II), in the anterolateral region of the left thigh, at Day 0.
Study NCT03251053 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Electronic cigarette use
Description: Replacement of tobacco smoking with electronic cigarette vaping
Study NCT03251053 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic cigarette use
Description: Replacement of tobacco smoking with electronic cigarette vaping
Study NCT03251053 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control regular cigarette smokers
Study NCT04709588 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo group
Description: subjects drank 50 ml every night for 14, 28 days
Study NCT04709588 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: collagen drinkss
Description: subjects drank 50 ml every night for 14, 28 days
Study NCT02476175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: Patients will keep the antimuscarinic providing some efficacy and that is tolerated and Mirabegron will be added (dual therapy).
Study NCT04064996 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine rehabilitation program patient education
Description: Patient education~All the patients were assessed with Wagner Classification, Diabetic Neuropathy Symptom (DNS) score, Diabetic Neuropathy Examination (DNE) score, Visual Analogue Scale (VAS), Leeds assessment of neuropathic symptoms and signs (LANSS), hand-held dynamometer, range of motion measurements, Semmes-Weinstein monofilament, two point discrimination test, circumference measurements, Foot and Ankle Ability Measure(FAAM), 6-minute walk test (6MWT) before and after the treatment.
Study NCT04064996 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine rehabilitation program + foot exercise training
Description: In addition to the patient education , foot exercise training will be performed. Patients will be applied exercise training consisted of aerobic, strengthening, sensory training and stretching exercises for 3 days/week, 8 weeks.~All the patients were assessed with Wagner Classification, Diabetic Neuropathy Symptom (DNS) score, Diabetic Neuropathy Examination (DNE) score, Visual Analogue Scale (VAS), Leeds assessment of neuropathic symptoms and signs (LANSS) ,hand-held dynamometer,range of motion measurements, Semmes-Weinstein monofilament, two point discrimination test,circumference measurements, Foot and Ankle Ability Measure(FAAM), 6-minute walk test (6MWT) before and after the treatment.
Study NCT00645268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sildenafil
Description: In the double-blind phase, patients received sildenafil 50 mg once daily during Week 1 (7 doses), followed by a daily dose of sildenafil 100 mg during the next 3 weeks.
Study NCT04242979 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaire about albumin use in liver cirrhosis
Description: 1. Permission to carry out the study will be obtained from the Faculty's Ethics Committee.~2. To achieve validity and reliability of the tool. It will be reviewed by two experts in the field of the study and necessary modification will be done.~3. A pilot study will be 10% done to test the clarity and feasibility of developed tool.~4. Each participant involved in the study will be assessed for his or her knowledge using (tool I).~5. Data will be collected by personal interview with participants or via fulfilling online questionnaire taking in consideration data confidentiality.~6. Application of the designed evidence based indications for human albumin use supported by the international guidelines will be done by researcher using (tool II).~7. Evaluate the effect of the designed evidence based indications for human albumin use supported by the international guidelines on physicians' knowledge after 1 month using (tool I) in a random sample of those physicians
Study NCT02214030 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Assiut Femoral Compression Device
Description: Assiut Femoral Compression Devices (AFCD) is a femoral compression system, The pressure dome is situated over the vessel puncture site in the groin and applies a mechanical pressure over the vessel puncture site to induce hemostasis.
Study NCT02214030 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Assiut Femoral Compression Device
Description: Assiut Femoral Compression Devices (AFCD) is a femoral compression system, The pressure dome is situated over the vessel puncture site in the groin and applies a mechanical pressure over the vessel puncture site to induce hemostasis.
Study NCT02306369 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internetdelivered exposure-based CBT
Description: The Internet-delivered exposure treatment is based on the well-established internet-delivered CBT-treatment for IBS in adults, and adapted for adolescents and their parents. The feasibility of the treatment were tested in a pilot study during 2012. Components in the treatment are exposure for symptoms and parent training. The purpose of the treatment is to reduce fearful and anxious responses to symptoms and lessen avoidance of symptoms in the adolescents, and to teach the parents how parental behavior can influence symptoms in children. Detailed behaviour analysis is made for each individual and instruction is given on how to gradually expose to symptoms to lessen fear for symptoms and widen the behavioral repertoire.
Study NCT01686945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Start doses of 5 mg and 10 mg with end dose of 20 mg. For oral administration.
Study NCT01686945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Start doses of 5 mg and 10 mg with end doses of either 20 mg or 40 mg. For oral administration.
Study NCT01686945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Start doses of 5 mg and 10 mg with end doses of either 20 mg, 40 mg or 60 mg. For oral administration.
Study NCT01686945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo semaglutide. For oral administration.
Study NCT01686945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo semaglutide with carrier. For oral administration.
Study NCT04639557 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BRIDGE Therapy Program
Description: The BRIDGE Therapy Program is a novel manualized therapy that incorporates key parenting concepts and related Dialectical Behavior Therapy (DBT) modules. The primary aim of the program is to promote self-regulation in the mother-child dyads. There are two components of the program: 1) the DBT section, which will follow the DBT Skills Training Manual 2nd Edition and target maternal mental health symptomology, and 2) the parent skill training materials, which have been designed to correspond to the four core DBT modules (i.e., Mindfulness, Emotion Regulation, Distress Tolerance, and Interpersonal Effectiveness) and to promote self-regulatory skill development and a positive parent-child relationship.
Study NCT04122118 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Chart Review
Description: Review of medical chart
Study NCT04122118 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive pharmacist-led education
Study NCT04122118 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT02415192 — intervention group
Intervention type: DRUG
Intervention: Levacalm
Study NCT02415192 — intervention group
Intervention type: DRUG
Intervention: Valsartan/amlodipine
Study NCT04069884 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: regional nodal irradiation
Description: external-beam radiotherapy (XRT)
Study NCT04069884 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: WBI
Description: Whole Breast Irradiation
Study NCT04069884 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: WBI
Description: Whole Breast Irradiation
Study NCT04069884 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: chestwall XRT
Description: chestwall irradiation
Study NCT04362202 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Water-based Sequential Preparatory Approach
Description: The experimental training consists of a sequential and a preparatory approach aimed at enhancing dynamic postural stability. The exercises followed a specific sequence starting from a kneeling position, proceeding to a sitting position and ending with a supine position. Step exercises preparatory for gait were performed using a step and two floating aids. Gait exercises were performed first with the upper limbs placed on two floating aids and then during a dual motor task (i.e., catching a ball thrown by the therapist).~The control aquatic therapy consists of water-based exercises, in line with suggestions of the Hydrotherapy Association of Chartered Physiotherapists Guidance on Good Practice in Hydrotherapy.~These consisted of warm-up exercises, stretching exercises for the lower limbs, recruitment exercises and walking exercises during each phase of gait (single stance, swing and double stance).
Study NCT04362202 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water-based Sequential Preparatory Approach
Description: The experimental training consists of a sequential and a preparatory approach aimed at enhancing dynamic postural stability. The exercises followed a specific sequence starting from a kneeling position, proceeding to a sitting position and ending with a supine position. Step exercises preparatory for gait were performed using a step and two floating aids. Gait exercises were performed first with the upper limbs placed on two floating aids and then during a dual motor task (i.e., catching a ball thrown by the therapist).~The control aquatic therapy consists of water-based exercises, in line with suggestions of the Hydrotherapy Association of Chartered Physiotherapists Guidance on Good Practice in Hydrotherapy.~These consisted of warm-up exercises, stretching exercises for the lower limbs, recruitment exercises and walking exercises during each phase of gait (single stance, swing and double stance).
Study NCT04472546 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: in-vivo mesure
Description: * for acne of the face subgroup and its associated control : face and inner side of the forearm~* for atopic dermatitis of the upper limb subgroup and its associated control: upper limb (hand excluded) and inner side of the forearm~* for vulgar plaque psoriasis subgroup and its associated control: upper limb (hand excluded) or lower limb and inner side of the forearm~* for telangiectasic erythrocouperosis papule of the face (rosacea) subgroup and its associated control: face and inner side of the forearm~* for seborrheic dermatitis of scalp subgroup and its associated control: scalp and inner side of the forearm
Study NCT04472546 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Scotch
Description: * for acne of the face subgroup and its associated control : face and inner side of the forearm~* for atopic dermatitis of the upper limb subgroup and its associated control: upper limb (hand excluded) and inner side of the forearm~* for vulgar plaque psoriasis subgroup and its associated control: upper limb (hand excluded) or lower limb and inner side of the forearm~* for telangiectasic erythrocouperosis papule of the face (rosacea) subgroup and its associated control: face and inner side of the forearm~* for seborrheic dermatitis of scalp subgroup and its associated control: scalp and inner side of the forearm
Study NCT04472546 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Lipid index
Description: * for acne of the face subgroup and its associated control : face~* for seborrheic dermatitis of scalp subgroup and its associated control: scalp~* for telangiectasic erythrocouperosis papule of the face (rosacea) subgroup and its associated control: face
Study NCT04472546 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Absorbant paper
Description: * for acne of the face subgroup and its associated control : face~* for seborrheic dermatitis of scalp subgroup and its associated control: scalp~* for telangiectasic erythrocouperosis papule of the face (rosacea) subgroup and its associated control: forehead
Study NCT04472546 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hydratation Index
Description: -for atopic dermatitis of the upper limb subgroup and its associated control: upper limb (hand excluded)
Study NCT04472546 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: TransEpidermal Water Loss
Description: -for atopic dermatitis of the upper limb subgroup and its associated control: upper limb (hand excluded)
Study NCT03161730 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: McGrath videolaryngoscopy
Description: Participants perform three intubation attempts using McGrath videolaryngoscope in the normal and cervical immobilized manikin by novice
Study NCT00645268 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: In the double-blind phase, patients received placebo once daily during Week 1 (7 doses), followed by a daily dose of placebo during the next 3 weeks.
Study NCT00645268 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: sildenafil
Description: Eligible subjects then entered an open-label phase during which all subjects received sildenafil 50 mg as needed for sexual activity for the next 2 weeks, which could be titrated to either 25 mg or 100 mg based on the investigator's assessment of efficacy and tolerability, for 10 weeks (12 weeks total).
Study NCT01852461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beractant
Description: Beractant;both initial and subsequent dosing is 100 mg/kg (4 mL/kg), which may be given every 6 hours up to four total doses
Study NCT03161730 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pentax videolaryngoscopy
Description: Participants perform three intubation attempts using Pentax Airway Scope in the normal and cervical immobilized manikin by novice
Study NCT03161730 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh laryngoscopy
Description: Participants perform three intubation attempts using Macintosh laryngoscope in the normal and cervical immobilized manikin by novice
Study NCT01084057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally
Study NCT01084057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Description: Given IV
Study NCT01084057 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01084057 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies